Shijiazhuang Yiling PharmaceuticalShijiazhuang Yiling Pharmaceutical was awarded the “Most Cooperative Industrial Brand Enterprise of Chinese Chain Drugstores”
Shijiazhuang Yiling Pharmaceutical
was awarded the “Most Cooperative Industrial Brand Enterprise of Chinese Chain Drugstores”
On July 15th, 2018 China's top 100 pharmaceutical industry list was held in Jinan. As the highlight of the 2019 National Pharmacy Week, “2019 China Chain Drugstore's Most Cooperative Industrial Brand Enterprise” was unveiled in Jinan Shandong Building! Yiling Pharmaceuticals praised “2019 China Chain Pharmacy Most Cooperative Industrial Brand Enterprise”.
This is the second industry honor that Lingling Pharmaceuticals has won after the “Top 100 Chinese Pharmaceutical Industry” in the 2019 pharmacy week.
The 2019 National Pharmacy Week and China Pharmaceutical Innovation and Development Summit, the theme of “Reconstruction of Value – Searching for Growth, Expanding Boundaries, and Exploring the Future”, under the current situation of rapid changes in policy and market environment and accelerated restructuring of the pharmaceutical retail industry, Look for new growth points in the hot policy of the pharmaceutical industry, develop and break through the development boundary in the new competitive environment, and seize the commanding heights of the future.
In the past 27 years, Yiling Pharmaceutical has always adhered to the market leading and technology-driven innovation development strategy, and created a unique operation mode of “theory-clinical-scientific research-industry-teaching”.
He has undertaken and completed more than 30 national-level major projects such as the national “Eleventh Five-Year” support, the national “Twelfth Five-Year Plan” major new drug creation, the national key research and development plan, and more than 10 patent new drugs. More than 350 patents and 5 national science and technology awards have made Yiling Pharmaceuticals the leader in China's pharmaceutical industry.
Under the guidance of the corporate tenet of “inheriting innovation and benefiting mankind”, we take healthy human beings as our own responsibility and benefit the society as our wish. Yiling Pharmaceutical has formed three major business segments of modern Chinese medicine, chemical pharmaceutical and health industry, and developed into a net asset of 7.5 billion. The top 20 pharmaceutical companies with a market value of around 20 billion (stock code 002603).
In 2018, Yiling Pharmaceutical achieved a total operating income of 4.815 billion yuan, a year-on-year increase of 17.98%, a net profit of 599 million yuan, a year-on-year increase of 10.82%, and a tax payment of 760 million yuan.